Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy.
Lau SCM, Ryan M, Weiss J, Fares AF, Garcia M, Schmid S, Kuang S, Kelly D, Tsao MS, Bradbury PA, Cho BCJ, Sun A, Raman S, Hope A, Giuliani M, Lok BH, Bezjak A, Liu G, Leighl NB, Shepherd FA, Sacher AG. Lau SCM, et al. Among authors: shepherd fa. JTO Clin Res Rep. 2021 Nov 2;2(12):100251. doi: 10.1016/j.jtocrr.2021.100251. eCollection 2021 Dec. JTO Clin Res Rep. 2021. PMID: 34917991 Free PMC article.
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.
Leighl NB, Burkes RL, Dancey JE, Lopez PG, Higgins BP, David Walde PL, Rudinskas LC, Rahim YH, Rodgers A, Pond GR, Shepherd FA. Leighl NB, et al. Among authors: shepherd fa. Clin Lung Cancer. 2003 Sep;5(2):107-12. doi: 10.3816/CLC.2003.n.024. Clin Lung Cancer. 2003. PMID: 14596693 Clinical Trial.
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA. Leighl NB, et al. Among authors: shepherd fa. J Clin Oncol. 2005 Apr 20;23(12):2831-9. doi: 10.1200/JCO.2005.04.044. J Clin Oncol. 2005. PMID: 15837997 Clinical Trial.
Erlotinib in previously treated non-small-cell lung cancer.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Shepherd FA, et al. N Engl J Med. 2005 Jul 14;353(2):123-32. doi: 10.1056/NEJMoa050753. N Engl J Med. 2005. PMID: 16014882 Free article. Clinical Trial.
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Bezjak A, et al. Among authors: shepherd fa. J Clin Oncol. 2006 Aug 20;24(24):3831-7. doi: 10.1200/JCO.2006.05.8073. J Clin Oncol. 2006. PMID: 16921034 Clinical Trial.
549 results